{
  "docId": "019de077-8566-7247-8a65-bb40d287c138",
  "docSlug": "3a5ef691e659aba2296672e3bbfa035c",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 36,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The slide combines a problem statement (clinical unmet need) with a market sizing chart.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/8",
  "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138",
  "deckJsonHref": "/decks/019de077-8566-7247-8a65-bb40d287c138.json",
  "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.44,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Estimated U.S. diagnosed patient population",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c08f67f7-9340-4aac-8eb2-ddb9ecc63c6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.38,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "Chronic, progressive infection; life threatening in some patients whose disease becomes refractory to available therapies. Coughing, chest tightness, fatigue leads to social isolation and quality of life impact. Only one FDA-approved therapy in treatment-refractory MAC, inhaled therapy. Other regimens rely on off-label uses with significant safety and tolerability issues.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "436d78de-f0be-40fd-97a4-3fee4c98c88b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.65,
        "y": 0.32
      },
      "kind": "metric",
      "text": "$1B+ opportunity",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6256ec1-7843-49bf-9237-eb1d40dfdae9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Substantial Market Opportunity in NTM for Oral EBO Once-a-Day dosing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "674c32ca-ceb6-4fbb-98c4-98115e328fda",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "697e3b5c-89a6-4420-a55b-f95d3ee5779a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document presents market sizing information for NTM lung disease and melioidosis.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}